Legal & General Group PLC Nymox Pharmaceutical Corp Transaction History

Legal & General Group PLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 12, 2021	SELL	$1.46 - $2.48 $6,975 - $11,849	-4,778 Closed	0 $0
Q3 2020 Nov 13, 2020	SELL	$2.3 - $3.66 $3,539 - $5,632	-1,539 Reduced 24.36%	4,778 $12,000
Q2 2020 Aug 14, 2020	BUY	$2.1 - $4.6 $13,265 - $29,058	6,317 New	6,317 $22,000
Q3 2019 Nov 13, 2019	SELL	$1.41 - $2.12 $6,232 - $9,370	-4,420 Closed	0 $0
Q2 2018 Aug 10, 2018	SELL	$3.12 - $4.33 $7,553 - $10,482	-2,421 Reduced 35.39%	4,420 $15,000
Q4 2017 Feb 13, 2018	BUY	$3.29 - $4.06 $22,506 - $27,774	6,841	6,841 $22,000

150K

Ticker NYMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 91,265,000
Market Cap $42.9M
Description
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperpl...

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

Stay updated on Legal & General Group PLC with notifications on news.